Nikhil Lalwani's FY2025 total of $10.28M ranks at the 81.5th percentile among 326 sector CEOs · sector median $4.22M · p75 $8.65M.
| Executive | Title | Salary | Bonus | Stock | Option | Incentive | Other | Total | Source |
|---|---|---|---|---|---|---|---|---|---|
| Nikhil Lalwani | CEO | $0.84M | — | $7.85M | — | $1.57M | $0.02M | $10.28M | SEC ↗ |
| Christopher K. Mutz | President, Head of Rare Disease | $0.47M | — | $2.13M | — | $0.48M | $0.32M | $3.40M | SEC ↗ |
| Stephen P. Carey | CFO | $0.52M | — | $2.13M | — | $0.58M | $0.02M | $3.25M | SEC ↗ |
| Meredith W. Cook | General Counsel | $0.46M | — | $1.46M | — | $0.38M | $0.02M | $2.32M | SEC ↗ |
| Ori Gutwerg | President, Generics | $0.48M | — | $1.35M | — | $0.48M | — | $2.31M | SEC ↗ |
Every figure links to its source SEC proxy (DEF 14A). Extraction: edgartools/ECD-XBRL.